CUMULATIVE INDEX 1992 Volume 19 March RENAL FUNCTION AND DISEASE, pages 1-273 June PREVENTION OF PREMATURITY, pages 275-487 September BRONCHOPULMONARY DYSPLASIA, pages 489-700 December APNEA AND SIDS, pages 701-961 Note: Page numbers of issue and article titles are in boldface type Abdominal mass, in urinary tract management of, 147-153 obstruction, 215 metabolic acidosis in, 152 Abortion rights; multiple gestation nutritional deficiency in, 152 reduction and, 352-353 obstructive, causes of, 143 Abuse, child. See Child abuse. outcome of, 154 substance. See Substance abuse. pathophysiology of, 140-141 Acid-base balance, in respiratory prerenal, causes of, 142-143 disorders, 228 sepsis in, 152-153 tubular function and, 47-49, 81, 168- Adenylate cyclase, in tocolytic therapy, 171 ; 369-371 urinary stone formation and, 182, 189 Adhesions, intrauterine, surgical Acidosis, hyperchloremic metabolic, in correction of, 319-322 renal disorders, 168, 215 Adrenal glands, brown fat around, in metabolic, in acute renal failure, 152 SIDS, 708 urinary stone formation and, 182, 189 Age factors, in sudden infant death renal tubular, 168-171 syndrome, infant, 728-729 Acro-renal syndromes, 201 maternal, 725 Acute life-threatening events. See Agenesis, of kidney, 88, 96-97, 200-202 Apparent life-threatening events. Airflow mechanics, in bronchopulmonary Acute renal failure, 139-158 dysplasia, assessment of, 658-660 causes of, 141-144 Airway, epithelial injury in, in continuous arteriovenous hemofiltration bronchopulmonary dysplasia, animal in, 153-154 models for, 527-528, 533-534 dialysis in, 153 narrowness of, polysomnography in, differential diagnosis of, 145-147 879 fluid overload in, 148-149 patency of, apnea and, 796-799 fluid therapy in, 242-243 control of, 773—788 hyperkalemia in, 151-152 during breathing, 777-781 hyperphosphatemia in, 152 during feedings, 781-784 hypertension in, 150-151 during regurgitation, 775 hypocalcemia in, 152 protection at face, 773-774 hyponatremia in, 149 reflexes in, 774-776 incidence of, 139-140 thoracic pressure and volume and, intrinsic, causes of, 143-144 776-777 management of, 147-153 reflexes of, in patency control, 744-776 pathophysiology of, 140-141 in respiration inhibition, 795 939 940 CUMULATIVE INDEX 1992 Airway (Continued) Amniotic fluid, dynamics of, 360 resistance of, in bronchopulmonary excess. See Polyhydramnios. dysplasia, assessment of, 657 functions of, 399 stimulation of, response to, apnea in, insufficient, pulmonary hypoplasia in, 796-799 511-513 Alanine-glyoxalate aminotransferase, in volume assessment methods for, in pre- stone formation, 181 term fetus, 442-443 Albuterol, in bronchopulmonary Amniotic fluid index, determination of, dysplasia, 570, 572-574, 666 360, 442 Aldosterone, in potassium metabolism, improvement of, amnioinfusion in, 404 37-38 Amphotericin B, renal effects of, 144 in renal tubular acidosis, 170-171 Ampicillin, in chorioamnionitis, 402 in sodium metabolism, 21-22 Analgesia, in delivery of low birth weight Alkalosis, hyperkalemic metabolic, in infant, 419 Bartter’s syndrome, 166-167 Anemia, maternal, prematurity and, 284— metabolic, urinary stone formation and, 285 182 Anemometry, hot-wire, in mechanical Allopurinol, in bronchopulmonary ventilation monitoring, 626 dysplasia, 530-531 Anencephaly, pulmonary hypoplasia and, ALTEs. See Apparent life-threatening events. 515 : Alveolar macrophage(s), growth factor Anesthesia, in delivery of low birth production by, 606-611 weight infant, 419 in lung injur}repair, 605 Angiotensin(s), glomerular filtration and, Alveolar macrophage-derived growth 8, 10 factor, production of, in lung injury, production of, 60-62 610 renal vascular resistance and, 4 Alveoli, epithelial cells of, maturity of, Angiotensin-converting enzyme (kininase 507, 509-510 Il), production of, 60-64 hyperoxia effects on, 550 Angiotensin-converting enzyme cellular events in, 604-605 inhibitors, in hypertension, 131 inflammatory response, 605 renal effects of, 255-256 hypoplasia of, 506 Angiotensinogen, production of, 60 surface complexity of, 507-510 Animal models, of bronchopulmonary Amiloride, renal effects of, 253 dysplasia. See under Amino acid(s), tubular transport of, Bronchopulmonary dysplasia. development of, 38-42 Anion gap, urinary, in renal tubular disorders of, 159-161 acidosis, 169 Aminophylline, renal effects of, 187 Anomalous lesions, in SIDS, 711 Amniocentesis, in premature membrane Antibiotics, in chorioamnionitis, 402 rupture, 387, 392 in premature membrane rupture, 387 infection from, 376 in tocolytic therapy, 375-378 therapeutic, in polyhydramnios, 362- Anticholinergic drugs, in 363 bronchopulmonary dysplasia, 570- Amnioinfusion, contraindications to, 404 571 drawbacks of, 406 Antidiuretic hormone, diabetes insipidus equipment for, 401-402 and, 171-172 in chorioamnionitis prevention, 402 respiratory disease and, 225-226 in fetal deformation prevention, 403 Antihypertensive drugs, renal effects of, © in premature membrane rupture, 399- 254-257 409 Antinatriuretic peptide, respiratory effects in ultrasonographic image improve- of, 225-226 ment, 403 Antioxidant(s), action of, 542 in umbilical cord compression preven- in bronchopulmonary dysplasia, 581— tion, 403 582 of artificial surfactant, 403 Antioxidant enzymes, activity of, 542-544 risks of, 403-404 augmentation of, 553-554 Amnionitis, detection of, 387 in late gestation, 545 preterm labor in, 376 in lung injury, 613 Amniorrhexis. See Membranes, premature deficiency of, in premature infant, 545- rupture of. 546, 552 |e ae CUMULATIVE INDEX 1992 941 in bronchopulmonary dysplasia, 524- incidence of, 810, 814 525, 531 interventions for, 917-918 synthesis of, nutritional supplements management of, 829, 831-832 for, 552 monitoring in, 881-882, 911-912 Antiporter system, in urine acidification, physiology of, 814-819 47-49 prenatal substance abuse exposure and, a,-Antitrypsin, in oxygen toxicity 857 protection, 554 SIDS risk after, 866 Anuria, in urinary tract obstruction, 215 terminology of, 809-810 Aorta, coarctation of, hypertension in, 126 Arousal responsiveness, in apnea, 780- Apnea, arousal in, 780-781 781 in airway patency control failure, 776 in asphyxia, 780-781 in feeding, 784 in SIDS, 760-763 obstructive, monitoring in, 918 Asphyxia, acute renal failure in, 143 polysomnography in, 879 arousal in, 760-763, 780-781 seizure-induced, polysomnography in, Aspirin, in prematurity prevention, 305— 881 317 with gastroesophageal reflux, monitor- intrauterine growth retardation, 311- ing of, 879-880 315 Apnea of infancy, definition of, 810 mechanism of action of, 305-307 in apparent life-threatening events. See preeclampsia, 308-311 Apparent life-threatening events. safety of, 315 in SIDS, 758-759 ATP-magnesium chloride, in acute renal monitoring for. See Monitoring, cardio- failure, 147-148 respiratory; Polysomnography. Atrial natriuretic factor, in sodium polysomnography. in, 871-889 regulation, 21-23 prenatal substance abuse exposure and, Atropine, in bronchopulmonary 854-856 dysplasia, 572 Apnea of prematurity, 789-808 Autocrine growth factors, in lung airway reflexes in, 792, 795 development, 514 airway responses to stimuli and, 796- Autopsy, in SIDS. See Sudden infant death 799 syndrome, pathologic findings in. central, 790 Autoregulation, of kidney function, central neural output modulation in, development of, 10-11 793-794 Autoresuscitation, failure of, in SIDS, 763 chest wall.activity in, 796-799 classification of, 789-790 definition of, 789 diagnosis of, 799 Bacteriuria, maternal, treatment of, 377- epidemiology of, 792-793 37 home monitoring in, 914 Baroreceptors, in sodium metabolism, hypercapneic responses in, 794-795 development of, 16-17 hypoxic responses in, 794—795 Barotrauma, pulmonary, animal models mixed type, 790 for, 526-527 natural history of, 792-793 Bartter’s syndrome, 166-167 obstructive, 790 Bed coverings, sudden infant death pathophysiology of, 793-799 syndrome and, 731 physiologic effects of, 790-792 Beta—2 microglobulin, tubular transport sudden infant death syndrome and, of, 52-53 727-728, 802-804 Beta-adrenergic agonists, in treatment of, 799-802 bronchopulmonary dysplasia, 570- Apparent life-threatening events, 809-838 571, 574, 666 apnea in, 802-804 in tocolytic therapy, 369-372 clinical presentation of, 819-820 Betamimetic agents, in placenta previa, definition of, 809-810 430 demographic factors in, 819 Bicarbonate, in renal tubular acidosis, 170 differential diagnosis of, 826 tubular transport of, development of, evaluation in, 829, 831 47-49, 81 fatal outcome of, 821-822, 826-827 Biophysical profile, in preterm fetal follow-up studies of, 820-822, 826-828 monitoring, 443-444 tires 942 CUMULATIVE INDEX 1992 Birth, breathing establishment at, 746-747 in apparent life-threatening events, Birth weight, low. See Low birth weight 814-815 infant. in bronchopulmonary dysplasia, assess- vs. bronchoptdmonary dysplasia inci- ment of, 654 dence, vu, 3-674 in neonate, 748-752 Bladder, obstruction of, 91-92 in sleep, 748-751 Bleeding, vaginal, as prematurity risk monitoring ot, analysis of, 876-877 factor, 283 periodic, vs. apnea, 789 Bleomycin, as lung injury model, 607-608 prenatal substance abuse, exposure and, Blood flow, renal. See Kidney, blood flow 854-856 in. recording of, 872-873 Blood gases, in apnea, monitoring of, 874 Bronchi, smooth muscle tone control in, Blood pressure, maintenance of, renin- 569-570 angiotensin system in, 61 Bronchoconstriction, focal, protective measurement of, 121-122 effect of, 571 normal values of, 123-124 Bronchodilators, in bronchopulmonary renal autoregulation and, 10-11 dysplasia, 569-574, 662 Body water. See Water (body). Bronchoprovocation test, in Bradycardia, in apnea, 791-792 bronchopulmonary dysplasia, 661- sudden infant death syndrome and, 662 i 766-767, 867-868 Bronchopulmonary dysplasia, animal Bradykinin, production of, 62-63 models for, 521-539 Brain, autopsy findings in, in SIDS, 709- baboon, 528-534 711 barotrauma, 526—527 hemorrhage in, in low birth weight in- healing phase, 531 fant, 417-418 high-frequency ventilation studies in, Brain stem dysfunction, in apnea, 793 526-527, 633, 636, 638 in SIDS, 758-767 initial injury stage, 529-531 arousal response. defects, 760-763 liquid ventilation in, 639-642 autopsy findings in, 709-711 mild-to-moderate, 531, 533-534 cardiac control abnormalities, 765-767 overview of, 522-523 chemoreceptor sensitivity defects, oxygen injury prevention, 525-526 759-760 oxygen toxicity, 523-525 dendritic spine abnormalities, 711 counseling on, 667-668 gasping failure, 763 definition of, 497, 673 gliosis, 708-710 vs. developmental outcome, 690-691 respiratory pattern abnormalities, developmental outcome in, 673-694 758-759 clinical studies on, 675-683 temperature regulation disorders, dexamethasone therapy in, 689 763-765 disease definition and, 690-691 Branchio-oto-renal syndrome, 201 environmental factors in, 688-689 Breast feeding, sudden infant death growth failure, 663, 674-675 syndrome and, 729 length of follow-up and, 686-688 Breath-holding spells, polysomnography mechanical ventilation effects on, 676, in, 880-881 684 Breathing. See also Respiratory. movement disorder, 690 airway patency control during, 777-781 socioeconomic factors in, 688 energetics of, in bronchopulmonary with intraventricular hemorrhage, dysplasia, 663 684-686 maturation of, 739-756 electrolyte disorders in. See Respiratory fetal patterns in, 740-746 disorders, electrolyte disorders in. historical considerations in, 739-740 environmental factors in, 688-689 in neonate, 748-752 etiology of, 541 transitions at birth, 746-747 - exercise intolerance in, 664 Breathing/respiratory patterns, growth failure in, 663, 674-675 abnormalities of. See also Apnea. historical aspects of, 489-492, 592 at birth, 746-747 long-term sequelae, 650-651 continuous, establishment of, 746-747 home monitoring in, 914 fetal, 740-746 incidence of, 673-674 pulmonary hypoplasia and, 513 infection in, 534 CUMULATIVE INDEX 1992 943 intraventricular hemorrhage with, de- surfactant supplementation, 591-602, velopmental outcome in, 684-686 664 introduction to, 489-495 vasodilator, 574-576 long-term pulmonary sequelae of, 649- vitamin A, 582-583 671 vs. Wilson-Mikity syndrome, 492-493 assessment of, 651-662 Brown fat, around adrenals, in SIDS, 708 airflow mechanics, 658-660 Bumetinide, renal effects of, 252-253 bronchoprovocation test, 661-662 gas exchange studies, 654-655 lung volume measurement, 655- 656 Caffeine, in apnea of prematurity, 799- pulmonary mechanics, 656-657 800 counseling in, 667-668 in apparent life-threatening events, 917 death, 667 in bronchopulmonary dysplasia, 570, exercise intolerance and, 664 572, 666 growth failure and, 663 Calcium, abnormal levels of. See historical perspectives of, 650-651 Hypercalciuria; Hypocalcemia. oxygen therapy in, 665-667 excretion of, nephrocalcinosis and, 184— pharmacologic interventions for, 665 188 reactive airway disease, 661-662 homeostasis of, in respiratory disorders, reduction of, 664-665 229 respiratory infections, 662-663 Calcium channel blockers, in placenta mechanical ventilation in. See under previa, 430 Mechanical ventilation. in tocolytic therapy, 378-379 mortality from, 489, 667 renal effects of, 256-257 movement disorder in, 690 Calcium gluconate, in hyperkalemia, 151 pathogenesis of; 490-491, 541-562, 616 in hypocalcemia, 152 animal studies in. See Bronchopulmo- Calcium stones, in kidney. See nary dysplasia, animal models for. Nephrocalcinosis. oxygen toxicity in, 523-526, 542-550 Calculi, in urinary tract. See undernutrition in, 550-552 Nephrocalcinosis; Urolithiasis. pathology of, 621 Captopril, in acute renal failure, 150 polysomnography in, 881 in hypertension, 131 prevention of, 493-494, 553-557, 583 renal effects of, 256 mechanical ventilation in. See under Carbon dioxide, excess of. See Mechanical ventilation. Hypercapnia/hypercarbia. pulmonary edema in, diuretic therapy exchange of, in bronchopulmonary dys- in, 564-569 plasia, assessment of, 654 pulmonary function testing in, 651-662 partial pressure of, in apnea, monitor- airflow mechanics, 658-660 ing of, 874 bronchoprovocation test, 661-662 Cardiac arrhythmias, monitoring of, gas exchange studies, 654-655 analysis of, 877 lung volume measurement, 655-656 in apnea, 873-874 pulmonary mechanics, 656-657 sudden infant death syndrome and, pulmonary hypertension in, vasodilator 727, 842, 867-868 therapy in, 574-576 Cardiac output, vs. renal blood flow, 3 respiratory infections in, 662-663 Cardiopulmonary reflex, development of, socioeconomic factors in, 688 16 therapy for, 563-590, 664-667 Cardiorespiratory control hypothesis, in animal studies in. See Bronchopulmo- SIDS. See under Sudden infant death nary dysplasia, animal models for. syndrome. antioxidant, 581-582 Cardiorespiratory monitoring. See bronchodilator, 569-574 Monitoring, cardiorespiratory. corticosteroids, 576-581, 664-665, 689 Cardiovascular symptoms, in diuretic, 564-569, 666 hypertension, 127 long-term sequelae of, 664-665 Carotid bodies, morphology of, in SIDS, mechanical ventilation in. See under 708 Mechanical ventilation. Catalase activity, in lung injury, 613 methylxanthines, 666 Catecholamines, renal vascular resistance oxygen therapy, 573, 575, 665-667 and, 4 944 CUMULATIVE INDEX 1992 Catecholamines (Continued) Congenital hypernephronic nephromegaly sodium metabolism and, 19-21 with tubular dysgenesis, 207 Catheter, cervical, in premature Continuous arteriovenous hemofiltration, membrane rupture management, in acute renal failure, 153-154 406-407 Continuous positive airway pressure, in Central hypoventilation syndrome, apnea of prematurity, 800-802 congenital, sudden infant death in bronchopulmonary dysplasia, 630 syndrome and, 842, 867 Contractions, uterine. See Uterus, activity Central nervous system. See also Brain. of. Cephalosporins, in chorioamnionitis, 402 Corticosteroids, in bronchopulmonary in premature membrane rupture, 407 dysplasia, 576-581 Cerclage procedure, in cervical long-term sequelae of, 664-665 incompetence, 326-327 in placenta previa, 430 in placenta previa, 431-432 in premature membrane rupture, 386- Ceruloplasmin, production of, in lung 387 in sodium homeostasis, in respiratory injury, 614 Cervical catheter, indwelling, in disease, 226-227 premature membrane rupture pulmonary hypoplasia and, 513-514 management, 406—407 urinary stone formation and, 187-188 Cervix, changes in, as prematurity risk Cortisol, sodium metabolism and, 24 factor, 281-282 Counseling, of SIDS parents. See under incompetence of, as prematurity risk Sudden infant death syndrome, parent factor, 280-281 involvement in. surgical correction of, 326-327 Creatinine, clearance of, in renal function evaluation, 73, 76-77 Cesarean delivery, of low birth weight infant, 412-417 serum, in renal function evaluation, 72, 78, 145 Chemoreceptor sensitivity, defects of, in SIDS, 759-760 Crib death. See Sudden infant death Chest wall stimulation, response to, syndrome. Cromolyn sodium, in bronchopulmonary apnea in, 796-799 dysplasia, 571, 573, 666 Child abuse, sudden infant death Crystal formation. See Nephrocalcinosis; syndrome and, 843-844, 936-937 Urolithiasis. pathologic findings in, 713 Childbirth, perceptions of, influence on Cultural factors, influence on obstetric ethics, 473-474 obstetric ethics, 474-475 Chlamydial infections, of genital tract, as Cvanosis, in sudden infant death syndrome, 728 prematurity risk factor, 284 Cyclo-oxygenase, inactivation of, in Chlorothiazide, in bronchopulmonary prematurity prevention, 306-307 dysplasia, 565-566, 666 Cysteamine, in cystinosis, 161 renal effects of, 253 Cystic kidney disease. See under Kidney Chord analysis, in bronchopulmonary disorders. dysplasia, 657 Cystine, tubular transport of, Chorioamnionitis, preterm labor in, 376 development of, 38 prevention of, 402 Cystinosis, 159-161 Citrate excretion, stone formation and, Cystourethrography, 86, 95 181, 188-189 in posterior urethral valves, 99 Clearance methodologies, in renal in ureteropelvic junction obstruction, function evaluation, 2—3, 72—78 218 Climate, SIDS and, 720-721 Cytomegalovirus infection, in SIDS, 712- Coarctation, aortic, hypertension in, 126 713 Cocaine exposure, hypertension in, 127 renal abnormalities from, 207 SIDS and, epidemiology of, 549-851 physiologic studies of, 854-857 Decision making, ethical issues in, conflict Coitus, prematurity and, 285 resolution in, 477—478 Computer-assisted mechanical ventilation, framework for, 471-473 in bronchopulmonary dysplasia, 628 Deferoxamine, toxicity of, 526 Congenital anomalies, of uterus, surgical Deformation, fetal, in premature correction of, 322-326 membrane rupture, reduction of, 404 CUMULATIVE INDEX 1992 945 Delivery methods, for low birth weight abuse of. See Substance abuse. infant, 411-423 as SIDS risk factors, 723-724 Demographic factors, in SIDS, 724-725 fetal breathing patterns and, 744-745 Desmopressin (DDAVP), in diabetes renal effects of. See Kidney function, drug insipidus, 171-172 effects on. Developmental outcome, in Ductus arteriosus, patency of, prenatal bronchopulmonary dysplasia. See indomethacin effects on, 374-375 under Bronchopulmonary dysplasia. Dysmorphic lesions, in SIDS, 711 Dexamethasone, in bronchopulmonary Dysplastic lesions, in SIDS, 711 dysplasia, 576-581, 689 in lung maturation acceleration, 554— 555 Diabetes insipidus, nephrogenic, 171-172 Eclampsia, prematurity and, 449-454 testing for, 80 Ectodermal dysplasia-ectrodactyly-cleft lip Diabetes mellitus, polyhydramnios in, 361 palate syndrome, 201-202 pulmonary hypoplasia and, 514 Edema, pulmonary. See Pulmonary edema. Dialysis, in acute renal failure, 153 Electroencephalography, in Diaphragmatic hernia, pulmonary polysomnography, 875 hypoplasia in, 510-511 Electrolyte(s). See also specific electrolyte. Diarrhea, fluid therapy in, 244 disorders of, in respiratory disorders. sudden infant death syndrome and, 729 See Respiratory disorders, electrolyte Diazoxide, in acute renal failure, 151 disorders in. in hypertension, 131 loss of, in preterm infants, 233-235 Diethylstilbestrol exposure, as prematurity Electromyography, in polysomnography, risk factor, 281 875 uterine anom<ties in, 325-326 Electrooculography, in polysomnography, Diltiazem, in bronchopulmonary 875 dysplasia, 574-575 Enalapril, in acute renal failure, 150 renal effects of, 256-257 renal effects of, 256 Dinamap device, in blood pressure Enalaprilat, in hypertension, 131 measurement, 122 renal effects of, 256 Diphtheria-tetanus-pertussis immunization, sudden infant death Endocrine function, of kidney, 59-68 development of, dopamine system, syndrome and, 730 20-21, 65-66 Dipyridamole, in intrauterine growth kallikrein-kinin system, 62-64 retardation, 311-315 in preeclampsia, 308-311 prostaglandin system, 23-24, 64-65 Disseminated intravascular coagulation, renin-angiotensin system, 21-22, acute renal failure in, 144 60-62 Diuretics, in acute renal failure, 147, 150 hypertension related to, 127 in bronchopulmonary dysplasia, 564— Endomyometritis, preterm labor in, 376 Environmental factors, in 569, 666 in hypertension, 130 bronchopulmonary dysplasia, renal effects of, 229, 251-253 developmental outcome and, 688-689 respiratory system effects of, 226 in sudden infant death syndrome, 843- Dobutamine, renal effects of, 260 844 Dopamine, in acute renal failure, 147 Epidermal growth factor, in Dopamine system, of kidney, bronchopulmonary dysplasia, 527- development of, 20-21, 65-66 528 drug effects on, 258-259 in lung injury, 609 Doppler techniques, in acute renal failure, pulmonary hypoplasia and, 514 147 Episiotomy, in delivery of low birth in blood pressure measurement, 122 weight infant, 413 Dormandy hypothesis, on oxygen toxicity Epithelial injury, in bronchopulmonary protection, 555 dysplasia, animal models for, 527- Down syndrome, alveolar hypoplasia in, 528, 533-534 506 Erythromycin, in tocolytic therapy, 378 Driving pressure, in bronchopulmonary Erythropoiesis, hepatic, in SIDS, 708 _ dysplasia, assessment of, 660 Esophagus, acidity of, recording of, 875- Drug(s). See also specific drug. 876 946 CUMULATIVE INDEX 1992 Estrogens, in intrauterine adhesion body water composition and, 235-237 management, 332 electrolyte loss and, 233-235 Ethics, in multiple gestation reduction, extremely low birth weight, 244-246 352-353 in gastrointestinal disorders, 244 in obstetric cases involving prematurity, in renal failure, 242-243 469-481 in respiratory distress, 243-244 beneficence-maternal autonomy bal- maintenance plan for, 239 ance in, 472 monitoring of, 240-242 childbirth perceptions in, 474-475 renal regulation of, 237-239 cultural factors in, 473-474 water loss and, 233-235 decisional conflict resolution in, 477- Fluid restriction, in acute renal failure, 149 478 Forced expiratory flow, in definitions in, 469-470 bronchopulmonary dysplasia, factors influencing decisions, 473-478 assessment of, 659-660 fetal status in, 475-477 Forceps delivery, of low birth weight framework for, 471—473 infant, 414 maternal autonomy in, 471-472 Fractional excretion, in acute renal failure, personal intuition in, 472-473 146 typical clinical questions, 470-471 in renal function evaluation, 75 Ethnicity, SIDS and, 719-720 Fraser syndrome, 202 Exercise intolerance, in Free radicals, in oxygen toxicity, 543 bronchopulmonary dysplasia, 664 Functional residual capacity, in EXOSURF surfactant preparation, 465 bronchopulmonary dysplasia, 627 Extracellular fluid volume, regulation of. assessment of, 655-656 See Sodium metabolism. Fungal infections, of urinary tract, 112- Extracorporeal membrane oxygenation, 114 hypertension in, 126 Furosemide, in acute renal failure, 147 Eye disorders, in hypertension, 128 in bronchopulmonary dysplasia, 565, 567-569 in respiratory disorders, 226, 244 renal effects of, 182-183, 187, 190, 251- Familial hypoplastic glomerulocystic 252, 226 kidney, 206-207 Fanconi-Bickel syndrome, 160 Fanconi pancytopenia syndrome, 202 Fanconi syndrome, 159-160 Gardnerella vaginalis infections, as Fatty acids, polyunsaturated, in oxygen prematurity risk factor, 284 toxicity protection, 555-557 Gas exchange, in bronchopulmonary Feeding, airway patency control during, dysplasia, assessment of, 654-655 781-784 Gasping, failure of, in SIDS, 763 Fetus, breathing patterns in, 740-746 Gastroesophageal reflux, apnea with, monitoring of, in premature membrane monitoring of, 879-880, 918-919 rupture, 393 documentation of, 875-876, 878 personhood of, in obstetric ethics, 475- sudden infant death syndrome and, 477 728, 866-867 preterm. see Preterm fetus. Gastrointestinal illness, sudden infant Fibroblast growth factors, production of, death syndrome and, 729 in lung injury, 610-611 Gender, SIDS and, 719 Fibrosis, pulmonary, altered gene Gene expression, after lung injury, 611- expression in, 614-616 616 growth factors in, 605-611 antioxidant enzymes, 614 Filicide, sudden infant death syndrome bronchopulmonary dysplasia and, 616 and, 843-844 surfactants, 611-613 Fitch-Fryns syndrome, 202 Genioglossus muscle, activity of, in Fluid challenge test, in acute renal failure, apnea, 796-799 145 Gentamycin, in chorioamnionitis, 402 Fluid overload, in acute renal failure, 148- Geographical factors, in SIDS, 720 149 Gestation, multiple. See Multiple gestation. Fluid requirements, in preterm infants, Gestational age, vs. bronchopulmonary 233-250 dysplasia incidence, 673-674 CUMULATIVE INDEX 1992 947 vs. nonstress test response, 439-441 Hering-Breuer reflex, 751-752, 797 Glomerular filtration, autoregulation of, Hernia, diaphragmatic, pulmonary 10-11 hypoplasia in, 510-511 development of, 7-10, 237-238 High-frequency ventilation, in estimation of, 76-77 bronchopulmonary dysplasia, 526- Glomerular maturation arrest, 143 527, 632-638 Glomerulocystic kidney disease, 206-207 Histamine, production of, in kidney, 66 Glucose, tubular reabsorption of, Hyaline membrane disease, animal development of, 49-51 models for, 522, 528-529 disorders of, 159-160, 164-166 bronchopulmonary dysplasia after, 621, Glutaric aciduria type II multiple acyl CoA 623-626 dehydrogenase deficiencies, 205-206 developmental outcome and, 687 Glutathione peroxidase, activity of, in definition of, 497 lung injury, 613 in postmature infant, 515 Glycine, tubular transport of, Hydralazine, in acute renal failure, 150 development of, 38-39 in bronchopulmonary dysplasia, 574- Growth, failure of, in bronchopulmonary 575 dysplasia, 663, 673-674 in hypertension, 130-131 retardation of, in Bartter’s syndrome, in preeclampsia, 451 166-167 Hydramnios. See Polyhydramnios. intrauterine. See Intrauterine growth Hydrochlorothiazide, in retardation. bronchopulmonary dysplasia, 565- water retention for, 235 566, 569 Growth factors, in bronchopulmonary in diabetes insipidus, 172 dysplasia, 527-528 renal effects of, 253 lung injury and, 605-611, 614 Hydronephrosis, bilateral, in urinary tract pulmonary hypoplasia and, 514 obstruction, 216 Growth hormone, in phosphate tubular imaging of, 88-92, 97-99 transport, 46-47 unilateral, in urinary tract obstruction, pulmonary hypoplasia and, 514 215 Guild for Infant Survival, 931 Hyperaldosteronism, in Bartter’s syndrome, 166-167 Hypercalciuria, in hyperprostaglandinuria with hypokalemia, 167-168 Hamartoblastoma, with multiple nephrocalcinosis and, 180, 184-188, congenital anomalies, 202 190-191 Head, paradoxical reflex of, 751-752 Hypercapnia/hypercarbia, breathing Heart, autopsy findings in, in SIDS, 705 patterns and, 749-750 Heart rate, fetal, nonstress test response fetal, 743-745 of, 439-442 in apnea, 790-791, 794-795 in apparent life-threatening events, 814, in apparent life-threatening events, 817 arousal response to, 814, 816 in sudden infant death syndrome, 765- in SIDS, 759-760 767, 856-857 arousal response to, 760-763 HELLP syndrome, prematurity and, 449- prenatal substance abuse exposure 454 and, 855-856 Hemangioma, in SIDS, 711 Hyperchloremic metabolic acidosis, in Hematocrit, maternal, prematurity and, renal tubular acidosis, 168 284-285 in urinary tract obstruction, 215 Hemodynamics, renal. See Kidney, Hyperkalemia, in acute renal failure, 151— hemodynamics of. 152 Hemofiltration, continuous arteriovenous, in preterm infants, extremely low birth in acute renal failure, 153-154 weight, 245 Hemorrhage, in placenta previa, fetal, 431 in renal tubular acidosis, 170-171 maternal, 429, 432 in respiratory disease, 227 intraventricular, bronchopulmonary treatment of, 245 dysplasia with, developmental out- Hyperkalemic metabolic alkalosis, in come in, 684-686 Bartter’s syndrome, 166—167 ‘in low birth weight infant, 417-418 Hyperoxaluria, in nephrocalcinosis, 181 pulmonary, in surfactant therapy, 464 Hyperoxia, animal models for, 523-526 948 CUMULATIVE INDEX 1992 Hyperoxia (Continued) prenatal substance abuse exposure oxygen toxicity and, 542-544 and, 855-856 with undernutrition, 551-553 tissue markers of, 707-709 protection against, 553-557 respiratory depression in, 794-795 pulmonary effects of, 603-619 Hysterosalpingography, in intrauterine cellular events, 604-605 adhesion diagnosis, 320 gene expression, 611-616 Hysteroscopy, in intrauterine adhesions, growth factors and, 605-611 320-321 in premature infant, 545-553 in uterine congenital anomaly manage- inflammatory response, 605 ment, 323-324 Hyperphosphatemia, in acute renal failure, 152 Hyperprostaglandinuria, in tubular disorders, 167-168 Imaging, of urinary tract. See under Hypertension, 121-137 Urinary tract. blood pressure measurement and, 121- Immunization, sudden infant death 122 syndrome and, 730 clinical presentation of, 127-129 Indomethacin, in hyperprostaglandinuria definition of, 124-125 with hypokalemia and hypercalciuria, etiology of, 125-127 168 evaluation of, 129 in placenta previa, 430 in acute renal failure, 150-151 in polyhydramnios, 363-364 in urinary tract obstruction, 215 in tocolytic therapy, 373-375 kallikrein secretion and, 63 renal effects of, 10, 257-258, 144 management of, 129-132 Infection (infant), in acute renal failure, prognosis for, 132 152-153 pulmonary, in bronchopulmonary dys- respiratory, in bronchopulmonary dys- plasia, vasodilator therapy in, 574- plasia, 534, 662-663 576 undernutrition and, 552 } vs. normal blood pressure values, 123- urinary tract, 112-114, 219-220 124 acute renal failure in, 144 Hyperthermia, sudden infant death Infection (maternal), as prematurity risk syndrome and, 763-765 factor, genital, 283-284 Hyperuricemia, in tubular disorders, 164 treatment of, 375-378 Hyperuricosuria, in nephrocalcinosis, 181 urinary tract, 283 Hypocalcemia, in acute renal failure, 152 prevention of, in premature membrane in-rickets, 163 rupture, 400, 402-403 Hypoglycemia, sudden infant death SIDS and, 723 . syndrome and, 842 Infertility, treatment of, multiple gestation Hypokalemia, in Bartter’s syndrome, 166- in. See Multiple gestation. 167 Inflammatory response, to hyperoxia, 605 in hyperprostaglandinuria with hyper- Insensible water loss, 233-235 calciuria, 167-168 replacement of, in acute renal failure, Hyponatremia, in acute renal failure, 149 149 in respiratory disorders, 224-227 Intermittent mandatory ventilation, in Hypophosphatemia, diet-related, 162 bronchopulmonary dysplasia, 628- in rickets, 162-164 630 Hypouricemia, in tubular disorders, 164 Intrauterine device, in adhesion Hypoventilation, central, sudden infant management, 321 death syndrome and, 842, 867 Intrauterine growth retardation, Hypovolemia, acute renal failure in, 142 prevention of, aspirin in, 311-315 Hypoxia/hypoxemia. See also Asphyxia. sudden infant death syndrome and, acute renal failure in, 143 726-727 breathing patterns and, fetal, 744 Intraventricular hemorrhage, infant, 750-751 bronchopulmonary dysplasia with, in apnea, 790-791 developmental outcome in, 684-686 in SIDS, arousal response to, 760-763 in hypertension, 128-129 chemoreceptor sensitivity and, 759- in low birth weight infant, 417-418 760 Inulin clearance, in renal function intrauterine, 722-723 evaluation, 76-77